Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab tesirine in relapsed or refractory DLL3+ SCLC
NCT03334487Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Planned start Mar 2018; status: withdrawn.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03334487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334487.